Keywords
Colorectal Neoplasms ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

484 Search results.

Colorectal Cancer Non-Protocol Therapy NCT00303628 - Non-Protocol Therapy Colorectal Cancer NCT00303628 E5204

- 3/25/15 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Header, Non-Protocol Therapy
E5204 Non-Protocol Therapy Form Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Had Surgery for Stage II or Stage III Rectal Cancer NCT00303628 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=089B4967-A7D1-3905-E044-0003BA3F9857

Eligibility Colorectal Cancer NCT00995202

- 9/20/21 - 1 form, 1 itemgroup, 14 items, 1 language
Itemgroup: Criteria
Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00995202

Eligibility Colorectal Cancer NCT00893503

- 9/20/21 - 1 form, 2 itemgroups, 19 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Scope Pilot Research Study; ODM derived from: https://clinicaltrials.gov/show/NCT00893503

Eligibility Metastatic Colorectal Cancer NCT02503150

- 9/20/21 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02503150

Eligibility Colorectal Cancer Screening NCT02481219

- 9/20/21 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Optimization of the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure; ODM derived from: https://clinicaltrials.gov/show/NCT02481219

Eligibility Colorectal Cancer NCT00755534

- 9/20/21 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC; ODM derived from: https://clinicaltrials.gov/show/NCT00755534

Eligibility Colorectal Cancer NCT00819169

- 9/20/21 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00819169

Eligibility Colorectal Cancer NCT00551213

- 9/20/21 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Determine the Activity of SCH 717454 in Subjects With Relapsed or Recurrent Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00551213

Eligibility Colorectal Cancer NCT00713128

- 9/20/21 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of the Incidence of Nausea and Vomiting in Patients With Colorectal Cancer Receiving Irinotecan-based Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00713128

Colorectal cancer metastases (NCT00268463) - Quality of Life Form Colorectal Cancer (NSABP C-09 NCT00268463)

- 9/20/21 - 1 form, 8 itemgroups, 94 items, 1 language
Itemgroups: Header, Treatment satisfaction, PHYSICAL WELL-BEING, Social and family well being, EMOTIONAL WELL-BEING, Functional Health, ADDITIONAL CONCERNS, Activity
NSABP Protocol C-09: Quality of Life Form Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer NCT00268463 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FC7E0FCB-064A-58CD-E034-0003BA3F9857

Eligibility NCT00932724 Metastatic Colorectal Cancer - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 25 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00932724

Eligibility Colorectal Neoplasm NCT00001576

- 9/20/21 - 1 form, 1 itemgroup, 15 items, 1 language
Itemgroup: Criteria
A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver; ODM derived from: https://clinicaltrials.gov/show/NCT00001576